Drug Trial Radar · NCT00620464
A Bioequivalence Study of IMPLANON and Radiopaque IMPLANON (34528)(P05720)
Last checked: Nov 19, 2026Latest source record: Feb 4, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
108
Actual
Start
May 2005
Primary completion
Feb 2009
Study completion Feb 2009
Sponsor
- Lead sponsor
- Organon and CoIndustry
- Sponsor type
- Industry
- First posted
- Feb 21, 2008
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- Who can join
- Female only, from 18 years, up to 40 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The primary purpose of this study is to demonstrate the bioequivalence of IMPLANON and Radiopaque IMPLANON.
Conditions
- Contraception
Interventions
Radiopaque ImplanonDrug
Radiopaque rod for 3 years
Implanon (etonogestrel implant)Drug
Implanon (etonogestrel implant) for 3 years
Primary outcomes
What the sponsor says the trial is designed to measure.
- Bioequivalence of Implanon® and Radiopaque Implanon.Time frame: 3 years
- Bioequivalence of Implanon® and Radiopaque ImplanonTime frame: 3 years
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.